$MTVA News

HC Wainwright & Co. Reiterates Buy on MetaVia, Maintains $20 Price Target

MetaVia Says All Enrolled Active Patients In Part 3 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For Obesity Treatment Completed Dose Titration, Now Receiving Highest Target Doses In Both Study Cohorts

MetaVia Files Prospectus For Offering $4M Common Shares

MetaVia Reports Up To 9.1% Weight Loss In Phase 1 DA-1726 Study, Showcases Combination Data For Metabolic Disease Programs At ADA 2026

MetaVia To Present Data On Obesity, Metabolic Therapies At Emerging Growth Conference

MetaVia Highlights New Phase 1 Data On DA-1726, Dual Oxyntomodulin Analog Agonist Targeting GLP1R And GCGR, In Late-Breaking Poster Presentation At EASL 2026

Why MetaVia Stock Is Surging On Friday?

Why MetaVia Stock Is Falling On Thursday?

MetaVia Announces Publication Of New Preclinical Research Supporting The Anti-Fibrotic Potential Of Vanoglipel In the Journal Biomolecules & Therapeutics

HC Wainwright & Co. Reiterates Buy on MetaVia, Maintains $20 Price Target

MetaVia Q1 EPS $(0.79) Misses $(0.74) Estimate

MetaVia To Present Obesity Drug DA-1726 Data At EASL Congress 2026 In Barcelona

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

MetaVia Says First Patient Dosed In Part 3 Of Phase 1 Clinical Trial Evaluating DA-1726, Dual Oxyntomodulin Analog Targeting Both GLP-1 And Glucagon Receptors

MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026…

HC Wainwright & Co. Maintains Buy on MetaVia, Lowers Price Target to $20

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate

OTC Markets Hosts Virtual Investor Presentation with H.H. Kim, CEO and President of MetaVia, and David Bautz, PhD, Senior Analyst at Zacks SCR

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control